IA
HZNP

IndexIQ Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

IndexIQ Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$429K Buy
4,076
+320
+9% +$31.2K 0.02% 443
2021
Q4 		$405K Buy
+3,756
New +$410K 0.01% 771

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IndexIQ Advisors's HZNP Position: Q1 2022 in Review

IndexIQ Advisors increased its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 8.5% in Q1 2022, buying an estimated $31.2K and bringing the position to 4,076 shares worth $429K. The position accounts for 0.02% of the portfolio, ranked #443.

IndexIQ Advisors first reported a position in HZNP in Q4 2021 and has held it in 2 quarters since. 620 funds tracked by Wall St. Rank hold HZNP as of Q1 2022.

  • IndexIQ Advisors held 4,076 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $429K as of Q1 2022.
  • IndexIQ Advisors bought 320 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2022, an estimated $31.2K.
  • Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.02% of IndexIQ Advisors's portfolio in Q1 2022, its #443 holding.
  • IndexIQ Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2021 and has held it in 2 quarters since.
  • 620 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.